{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:53:32Z","timestamp":1791273212595,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373121"],"award-info":[{"award-number":["82373121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503779"],"award-info":[{"award-number":["82503779"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M771981"],"award-info":[{"award-number":["2025M771981"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025T180558"],"award-info":[{"award-number":["2025T180558"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2024A03J1222"],"award-info":[{"award-number":["2024A03J1222"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024ZD0520000"],"award-info":[{"award-number":["2024ZD0520000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024ZD0520004"],"award-info":[{"award-number":["2024ZD0520004"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2505105"],"award-info":[{"award-number":["2022YFC2505105"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lungcan.2026.109543","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:44:16Z","timestamp":1784331856000},"page":"109543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["First-line treatment for unresectable pulmonary lymphoepithelial carcinoma: A real-world comparison of platinum-based doublet chemotherapy with or without PD-1 inhibitors"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4693-4396","authenticated-orcid":false,"given":"Lipeng","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8182-5634","authenticated-orcid":false,"given":"Wenjun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.109543_b0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109543_b0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1440-1843.2006.00910.x","article-title":"Lymphoepithelioma-like carcinoma of the lung","volume":"11","author":"Ho","year":"2006","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109543_b0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/1097-0142(19950801)76:3<413::AID-CNCR2820760311>3.0.CO;2-X","article-title":"Primary lymphoepithelioma-like carcinoma of the lung. A clinicopathologic study of 11 cases","volume":"76","author":"Chan","year":"1995","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109543_b0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/path.1711740405","article-title":"Incidence of latent infection of Epstein\u2013Barr virus in lung cancers\u2014an analysis of EBER1 expression in lung cancers by in situ hybridization","volume":"174","author":"Kasai","year":"1994","journal-title":"J. Pathol."},{"key":"10.1016\/j.lungcan.2026.109543_b0025","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.2147\/OTT.S241337","article-title":"Pulmonary lymphoepithelioma-like carcinoma: a mini-review","volume":"13","author":"Hu","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109543_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240729","article-title":"The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: a systematic review and meta-analysis","volume":"15","author":"Tang","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109543_b0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41392-020-00382-6","article-title":"Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lungcan.2026.109543_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107220","article-title":"Neoadjuvant immunotherapy in patients with pulmonary lymphoepithelioma-like carcinoma","volume":"181","author":"Hong","year":"2023","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109543_b0045","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41379-019-0391-9","article-title":"A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung","volume":"33","author":"Xie","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2026.109543_b0050","doi-asserted-by":"crossref","first-page":"S1577","DOI":"10.1016\/j.annonc.2022.10.383","article-title":"345P First-line gemcitabine-platinum chemotherapy in relapsed or metastatic pulmonary lymphoepithelioma-like carcinoma: a tertiary centre experience","volume":"33","author":"Cheung","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109543_b0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.21037\/tlcr-22-256","article-title":"Efficacy and safety of gemcitabine and capecitabine combination for patients with previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective single-arm cohort study","volume":"12","author":"Zou","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109543_b0060","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2147\/OTT.S84234","article-title":"Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma","volume":"8","author":"Wang","year":"2015","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.lungcan.2026.109543_b0065","doi-asserted-by":"crossref","first-page":"33019","DOI":"10.18632\/oncotarget.5028","article-title":"PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival","volume":"6","author":"Fang","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109543_b0070","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.lungcan.2015.03.017","article-title":"PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: a potential rationale for immunotherapy","volume":"88","author":"Chang","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109543_b0075","article-title":"Efficacy and safety of immunotherapy in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: a multicenter retrospective study","volume":"17","author":"Yang","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109543_b0080","article-title":"Sintilimab plus chemotherapy for first-line treatment of advanced pulmonary lymphoepithelioma-like carcinoma: phase 2 trial","volume":"6","author":"Lin","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.lungcan.2026.109543_b0085","article-title":"PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2026.109543_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108855","article-title":"Long-term survival with PD-1\/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis","volume":"211","author":"Tang","year":"2026","journal-title":"Lung Cancer"},{"issue":"21","key":"10.1016\/j.lungcan.2026.109543_b0095","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109543_b0100","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"20","key":"10.1016\/j.lungcan.2026.109543_b0105","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109543_b0110","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109543_b0115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.lungcan.2019.09.007","article-title":"First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma","volume":"137","author":"Lin","year":"2019","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109543_b0120","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.cllc.2018.12.014","article-title":"Clinical features and prognosis of pulmonary lymphoepithelioma-like carcinoma: summary of eighty-five cases","volume":"20","author":"Qin","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109543_b0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2021.05.022","article-title":"A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma","volume":"153","author":"Lee","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109543_b0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/cells11010032","article-title":"Immunotherapy in nonendemic nasopharyngeal carcinoma: real-world data from two nonendemic regions","volume":"11","author":"Economopoulou","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109543_b0135","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","article-title":"Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109543_b0140","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S1470-2045(22)00505-8","article-title":"International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109543_b0145","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/cac2.12100","article-title":"Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma","volume":"40","author":"Tan","year":"2020","journal-title":"Cancer Commun."},{"issue":"15","key":"10.1016\/j.lungcan.2026.109543_b0150","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2015-09-672030","article-title":"The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases","volume":"127","author":"Kanakry","year":"2016","journal-title":"Blood"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:25:42Z","timestamp":1791271542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S0169500226006045"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109543","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line treatment for unresectable pulmonary lymphoepithelial carcinoma: A real-world comparison of platinum-based doublet chemotherapy with or without PD-1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109543"}}